tetano
Editor, Senior Moderator
Int J Infect Dis
. 2020 Jul 4;S1201-9712(20)30542-7.
doi: 10.1016/j.ijid.2020.06.107. Online ahead of print.
Potential Effective Treatment for COVID-19: Systematic Review and Meta-Analysis of the Severe Infectious Disease With Convalescent Plasma Therapy
Mengyao Sun[SUP] 1 [/SUP], Yinghui Xu[SUP] 1 [/SUP], Hua He[SUP] 1 [/SUP], Li Zhang[SUP] 2 [/SUP], Xu Wang[SUP] 1 [/SUP], Qing Qiu[SUP] 3 [/SUP], Chao Sun[SUP] 1 [/SUP], Ye Guo[SUP] 1 [/SUP], Shi Qiu[SUP] 1 [/SUP], Kewei Ma[SUP] 4 [/SUP]
Affiliations
Abstract
Background: Convalescent plasma (CP) has been used successfully to treat many types of infectious diseases, and it has shown initial effects in the treatment of the emerging 2019 coronavirus disease (COVID-19). However, its curative effect and feasibility have yet to be confirmed by formal evaluation and well-designed clinical trials. To explore the effectiveness of treatment and predict the potential effect of CP for COVID-19, studies of different types of infectious diseases treated with CP were included in this systematic review and meta-analysis.
Methods: Related studies were obtained from databases and screened based on the inclusion criteria. The data quality was assessed, and the data were extracted and pooled for analysis.
Results: We included 40 studies on CP treatment for infectious diseases We found that CP treatment could reduce the risk of mortality with a low incidence of adverse events, promote the production of antibodies, show the decline in viral load, and shorten the disease course. A meta-analysis of 15 controlled studies showed that there was a significantly lower mortality rate in the group treated with CP (pooled OR = 0.32, 95% CI: 0.19-0.52, P < 0.001, I[SUP]2[/SUP] = 54%) than in the control groups. Studies were mostly of low or very low quality with a moderate or high risk of bias. The sources of clinical and methodological heterogeneity were identified. The exclusion of heterogeneity indicated that the results were stable.
Conclusions: CP therapy has some curative effect and is well tolerated to treat infectious diseases. It is a potentially effective treatment for COVID-19.
Keywords: convalescent plasma (CP); coronavirus disease 2019 (COVID-19); infectious disease; meta-analysis.
. 2020 Jul 4;S1201-9712(20)30542-7.
doi: 10.1016/j.ijid.2020.06.107. Online ahead of print.
Potential Effective Treatment for COVID-19: Systematic Review and Meta-Analysis of the Severe Infectious Disease With Convalescent Plasma Therapy
Mengyao Sun[SUP] 1 [/SUP], Yinghui Xu[SUP] 1 [/SUP], Hua He[SUP] 1 [/SUP], Li Zhang[SUP] 2 [/SUP], Xu Wang[SUP] 1 [/SUP], Qing Qiu[SUP] 3 [/SUP], Chao Sun[SUP] 1 [/SUP], Ye Guo[SUP] 1 [/SUP], Shi Qiu[SUP] 1 [/SUP], Kewei Ma[SUP] 4 [/SUP]
Affiliations
- PMID: 32634589
- DOI: 10.1016/j.ijid.2020.06.107
Abstract
Background: Convalescent plasma (CP) has been used successfully to treat many types of infectious diseases, and it has shown initial effects in the treatment of the emerging 2019 coronavirus disease (COVID-19). However, its curative effect and feasibility have yet to be confirmed by formal evaluation and well-designed clinical trials. To explore the effectiveness of treatment and predict the potential effect of CP for COVID-19, studies of different types of infectious diseases treated with CP were included in this systematic review and meta-analysis.
Methods: Related studies were obtained from databases and screened based on the inclusion criteria. The data quality was assessed, and the data were extracted and pooled for analysis.
Results: We included 40 studies on CP treatment for infectious diseases We found that CP treatment could reduce the risk of mortality with a low incidence of adverse events, promote the production of antibodies, show the decline in viral load, and shorten the disease course. A meta-analysis of 15 controlled studies showed that there was a significantly lower mortality rate in the group treated with CP (pooled OR = 0.32, 95% CI: 0.19-0.52, P < 0.001, I[SUP]2[/SUP] = 54%) than in the control groups. Studies were mostly of low or very low quality with a moderate or high risk of bias. The sources of clinical and methodological heterogeneity were identified. The exclusion of heterogeneity indicated that the results were stable.
Conclusions: CP therapy has some curative effect and is well tolerated to treat infectious diseases. It is a potentially effective treatment for COVID-19.
Keywords: convalescent plasma (CP); coronavirus disease 2019 (COVID-19); infectious disease; meta-analysis.